Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Merck
Dow
Mallinckrodt
Moodys

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,343,995

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,343,995
Title:Biphenyl compounds useful as muscarinic receptor antagonists
Abstract: This invention provides compounds of formula I: ##STR00001## wherein a, b, c, d, m, n, p, s, t, W, Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, and R.sup.8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Inventor(s): Mammen; Mathai (Menlo Park, CA), Ji; YuHua (Palo Alto, CA), Mu; YongQi (Los Altos, CA), Husfeld; Craig (Redwood City, CA), Li; Li (Sunnyvale, CA)
Assignee: THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)
Application Number:16/130,076
Patent Claims: 1. A method for producing bronchodilation in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a pharmaceutically acceptable carrier and biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piper- idin-4-yl ester or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical composition is administered to the mammal in an amount sufficient to provide about 10 .mu.g/day to about 200 .mu.g/day of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]-methylamino}ethyl)pipe- ridin-4-yl ester or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the pharmaceutical composition is administered by inhalation.

3. The method of claim 1, wherein the pharmaceutical composition is administered using a nebulizer inhaler.

4. The method of claim 1, wherein the pharmaceutical composition is administered in a single daily dose.

5. The method of claim 1, wherein the pharmaceutical composition comprises a pharmaceutically acceptable aqueous carrier.

6. The method of claim 5, wherein the pharmaceutical composition has a pH in the range of from 3 to 8.

7. The method of claim 5, wherein the pharmaceutical composition further comprises a buffer.

8. The method of claim 7, wherein the buffer is a sodium chloride citric acid buffer.

9. The method of claim 5, wherein the pharmaceutical composition is an isotonic aqueous solution.

10. The method of claim 9, wherein the isotonic aqueous solution comprises about 0.05 .mu.g/mL to about 10 mg/mL of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)- piperidin-4-yl ester or a pharmaceutically acceptable salt thereof.

11. The method of claim 1, wherein the pharmaceutical composition further comprises a .beta..sub.2 adrenergic receptor agonist.

12. The method of claim 1, wherein the pharmaceutical composition further comprises a steroidal anti-inflammatory agent.

13. A method for producing bronchodilation in a human patient, the method comprising administering to the patient by inhalation a pharmaceutical composition comprising a pharmaceutically acceptable carrier and biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piper- idin-4-yl ester or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical composition is administered to the patient in an amount sufficient to provide about 10 .mu.g/day to about 200 .mu.g/day of biphenyl-2-ylcarbamic acid 1( 2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]-methylamino}ethyl)piperid- in-4-yl ester or a pharmaceutically acceptable salt thereof.

14. The method of claim 13, wherein the pharmaceutical composition is administered using a nebulizer inhaler.

15. The method of claim 13, wherein the pharmaceutical composition is administered in a single daily dose.

16. The method of claim 13, wherein the pharmaceutical composition comprises a pharmaceutically acceptable aqueous carrier.

17. The method of claim 16, wherein the pharmaceutical composition has a pH in the range of from 3 to 8.

18. The method of claim 16, wherein the pharmaceutical composition further comprises a buffer.

19. The method of claim 18, wherein the buffer is a sodium chloride citric acid buffer.

20. The method of claim 16, wherein the pharmaceutical composition is an isotonic aqueous solution.

21. The method of claim 20, wherein the isotonic aqueous solution comprises about 0.05 .mu.g/mL to about 10 mg/mL of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)- piperidin-4-yl ester or a pharmaceutically acceptable salt thereof.

22. The method of claim 13, wherein the pharmaceutical composition further comprises a .beta..sub.2 adrenergic receptor agonist.

23. The method of claim 13, wherein the pharmaceutical composition further comprises a steroidal anti-inflammatory agent.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Express Scripts
Dow
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.